Crescent Biopharma, Inc.
CBIO
$10.35
-$0.75-6.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | 10.84M | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 10.84M | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | 10.84M | -- | -- | ||
| SG&A Expenses | 7.31M | 5.54M | 8.95M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 102.34M | 25.89M | 21.03M | ||
| Operating Income | -91.49M | -25.89M | -21.03M | ||
| Income Before Tax | -90.40M | -24.61M | -21.79M | ||
| Income Tax Expenses | 2.00M | -- | -- | ||
| Earnings from Continuing Operations | -92.40M | -24.61M | -21.79M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -92.40M | -24.61M | -21.79M | ||
| EBIT | -91.49M | -25.89M | -21.03M | ||
| EBITDA | -91.44M | -25.86M | -21.03M | ||
| EPS Basic | -4.01 | -1.27 | -4.93 | ||
| Normalized Basic EPS | -2.45 | -0.79 | -3.08 | ||
| EPS Diluted | -4.01 | -1.27 | -4.93 | ||
| Normalized Diluted EPS | -2.45 | -0.79 | -3.08 | ||
| Average Basic Shares Outstanding | 23.06M | 19.43M | 4.42M | ||
| Average Diluted Shares Outstanding | 23.06M | 19.43M | 4.42M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||